New blood filter could save lives in septic shock
NCT ID NCT06692036
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new blood-filtering method called adaptive blood purification (ABP) for people with septic shock. The treatment aims to remove inflammatory substances from the blood. 276 adults in intensive care will be randomly assigned to receive either standard care or standard care plus two 6-hour ABP sessions. The main goal is to see if ABP reduces deaths within 90 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Adaptive blood purification (a blood-filtering procedure that removes inflammatory substances, with or without dialysis)
- What this could lead to
- If it works, this could offer a new way to reduce deaths from septic shock by filtering harmful substances from the blood.
- What could go wrong
- This is an early-stage study with no prior proof of benefit. The procedure is complex and may not improve survival. Risks include complications from blood filtering.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 276 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 82 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adult patients admitted to intensive care unit (ICU), 18 years old ≤ age ≤ 82 years old; 2. Meeting the diagnostic criteria for septic shock (Sepsis 3.0), and the onset time of septic shock ≤ 24 hours; 3. Systemic inflammatory response syndrome (SIRS) ≥ 3 points; 4. Sequential organ failure assessment (SOFA) ≥ 6 points; 5. Voluntarily sign the informed consent form before the trial, and agree to participate in all visits, examinations, and treatments according to the requirements of the research plan. Exclusion Criteria: 1. Patients who have received blood purification treatment within 1 week for any reason; 2. Patients with congenital or acquired immunodeficiency diseases, or those who have received organ transplantation; 3. Patients who have received immunosuppressive drugs (mycophenolate, cyclophosphamide, FK506, etc.) within 28 days before enrollment; 4. Patients who received continuous treatment (≥ 3 days) with more than 10 mg/day of prednisolone (or other hormones at equivalent doses) within 28 days before enrollment; 5. Patients with active bleeding (requiring blood transfusion \> 3 units in the past 24 hours); 6. Patients with malignant tumors, those who cannot remove the lesions (such as surgical patients who cannot undergo surgical treatment); 7. End-stage organ failure (end-stage pulmonary heart disease, brain death, chronic liver disease combined with hepatic encephalopathy); 8. Platelet count \< 30×10\^9/L or neutrophil count \< 0.5×10\^9/L; 9. Patients who require supportive treatment due to acute pulmonary embolism or severe congestive heart failure; 10. The mean arterial blood pressure (MAP) cannot be maintained ≥ 65 mmHg after receiving vasoactive drugs and fluid resuscitation treatment; 11. Patients who have participated or participated in another clinical study within 28 days before enrollment; 12. Patients who are allergic to extracorporeal circulation materials, perfusion device materials or have a history of other severe allergies, or those who have heparin-associated thrombocytopenia; 13. Patients who are inappropriate for participating, such as pregnant or lactating women, patients with severe mental and neurological diseases, and those with a history of alcoholism that cannot be terminated.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Septic shock are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Chao Yang Hospital
Beijing, Beijing Municipality, 100020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chilling fever: can cooling septic shock patients save lives?
- Bedside eye scans may reveal hidden blood flow problems in septic shock
- Can two blood markers catch sepsis before it turns deadly?
- Two cheap blood ratios put to the test as sepsis death predictors
- Can a bedside ultrasound predict which septic shock patients will stop breathing on their own?
- Can a computer model speed up sepsis blood tests?